X0306 4 2021-03-23 0 0001789769 Instil Bio, Inc. TIL 0001851041 Crouch Bronson C/O INSTIL BIO, INC. 3963 MAPLE AVENUE, SUITE 350 DALLAS TX 75219 1 1 1 0 CEO and Chairman Common Stock 2021-03-23 4 C 0 30000000 A 30000000 I See footnote Common Stock 2021-03-23 4 C 0 6098799 A 36098799 I See footnote Common Stock 2021-03-23 4 C 0 1431274 A 37530073 I See footnote Common Stock 2021-03-23 4 P 0 450000 20.00 A 37980073 I See footnote Common Stock 2537873 D Common Stock 2399999 I See footnote Series A Preferred Stock 2021-03-23 4 C 0 25000000 0.00 D Common Stock 30000000 0 I See footnote Series B Preferred Stock 2021-03-23 4 C 0 5082333 0.00 D Common Stock 6098799 0 I See footnote Series C Preferred Stock 2021-03-23 4 C 0 1192729 0.00 D Common Stock 1431274 0 I See footnote Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date. The securities are held by Curative Ventures V LLC (the "LLC"). CV-Immetacyte Ultimate Manager LLC ("Ultimate Manager") is the general partner of CV-Immetacyte Manager LP, the general partner of the LLC. The Reporting Person is the manager of Ultimate Manager and disclaims Section 16 beneficial ownership of such securities except to the extent of his pecuniary interest therein. The securities are held by SB2A LP. The Reporting Person is the manager of SB2A Management LLC, the general partner and manager of SB2A LP. /s/ Madison Jones, Attorney-in-Fact 2021-03-25